PFE GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Pfizer Inc
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About the Pfizer, Astellas and Merck Collaboration Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).
Did you know?
Free cash flow has been growing at -2.5% annually.
Current Price
$26.67
-0.49%GoodMoat Value
$17.95
32.7% overvaluedProfile
Valuation (TTM)
Market Cap$151.64B
P/E19.52
EV$203.41B
P/B1.75
Shares Out5.69B
P/Sales2.42
Revenue$62.58B
EV/EBITDA14.39
Pfizer Inc (PFE) Quality Analysis
GoodMoat Analysis
Pfizer's quality profile is unfavourable for a value investor seeking durable moats and high returns. While it generates free cash flow and pays a substantial dividend, its profitability metrics are weak and deteriorating, with a low ROE and declining margins. The business lacks the high-quality hallmarks of a strong moat and consistent operational leverage.
Read full analysis
Pfizer's financial quality presents significant concerns when measured against the GoodMoat framework. Key profitability metrics are weak: the company's Return on Equity (ROE) of 9.0% falls far short of the high-quality threshold of 15-20% for Return on Invested Capital (ROIC), indicating poor returns on shareholder capital. Profitability is also deteriorating, with a negative revenue growth of -1.2% YoY and an operating margin of 12.0%, which is low for a pharmaceutical leader and suggests a lack of pricing power or operating leverage. The 5.9% Free Cash Flow (FCF) yield is positive, but the framework looks for FCF margins above 10-15%, which this yield implies is not being achieved on a margin basis. The debt/equity ratio of 0.75 is manageable but does not indicate the substantial net cash position preferred for a high-quality rating. Regarding moat identification, Pfizer likely scores low on the 14-point scale. While it may have elements like regulatory barriers (patents) and a strong brand, these are not currently translating into durable high returns or growth, as evidenced by the financials. The competitive position is challenged post-pandemic, with key products facing patent cliffs and revenue declining, which aligns with a 'Low Disruption Risk' score but not with strong moat characteristics like Pricing Power or Proprietary Data that drive superior economics.
PFE Profitability
Profitability trend analysis coming soon
PFE Growth
Growth trend analysis coming soon
PFE Financial Health
Financial health indicators coming soon
PFE Quality & Fundamental Analysis
Pfizer Inc (PFE) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. This quality analysis page evaluates Pfizer Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Pfizer Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 12.42% and a return on equity (ROE) of 8.99%. Return on assets (ROA) stands at 3.73%.
The debt-to-equity ratio is 0.75, with a current ratio of 1.16. Operating margin is 12.02%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Pfizer Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.